Literature DB >> 20563479

Left internal thoracic artery and saphenous vein as a composite graft: 8-year angiographic follow-up study.

José Glauco Lobo Filho1, Heraldo Guedis Lobo Filho, Francisco José Cabral Mesquita, Jaime Paula Pessoa Linhares Filho.   

Abstract

The use of a composite graft with left internal thoracic artery (LITA) and arterial or saphenous vein (SV) grafts can allow the complete revascularization of the left coronary system (LCS) without cardiopulmonary bypass (CPB) and without ascending aorta manipulation (AAM), in order to reduce some complications in the immediate postoperative. This study shows 8-year angiographic follow-up results of two patients underwent no-touch aorta off-pump coronary artery bypass grafting (CABG) using LITA and SV as a composite graft to supply LCS.

Entities:  

Mesh:

Year:  2010        PMID: 20563479     DOI: 10.1590/s0102-76382010000100024

Source DB:  PubMed          Journal:  Rev Bras Cir Cardiovasc


  3 in total

1.  Distribution of saphenous vein valves and its practical importance.

Authors:  Isabella Batista Martins Portugal; Igor de Lima Ribeiro; Célio Fernando de Sousa-Rodrigues; Rodrigo Freitas Monte-Bispo; Amauri Clemente da Rocha
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

2.  Intraoperative Analysis of Flow Dynamics in Arteriovenous Composite Y Grafts.

Authors:  Heraldo Guedis Lobo; José Glauco Lobo; Matheus Duarte Pimentel; Bruno Gadelha Bezerra Silva; Camylla Santos de Souza; Marília Leitão Montenegro; Maria Cláudia de Azevedo Leitão; Francisco Vagnaldo Fechine Jamacuru
Journal:  Braz J Cardiovasc Surg       Date:  2016 Sep-Oct

3.  Composite versus conventional coronary artery bypass grafting strategy for the anterolateral territory: study protocol for a randomized controlled trial.

Authors:  Ariane Drouin; Nicolas Noiseux; Carl Chartrand-Lefebvre; Gilles Soulez; Samer Mansour; Jan-Alexis Tremblay; Fadi Basile; Ignacio Prieto; Louis-Mathieu Stevens
Journal:  Trials       Date:  2013-08-26       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.